Annual Operating Expenses
$270.63 M
-$23.43 M-7.97%
December 31, 2023
Summary
- As of February 8, 2025, KPTI annual total operating expenses is $270.63 million, with the most recent change of -$23.43 million (-7.97%) on December 31, 2023.
- During the last 3 years, KPTI annual operating expenses has fallen by -$6.60 million (-2.38%).
- KPTI annual operating expenses is now -11.18% below its all-time high of $304.69 million, reached on December 31, 2021.
Performance
KPTI Operating Expenses Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Operating Expenses
$63.77 M
-$5.67 M-8.17%
September 30, 2024
Summary
- As of February 8, 2025, KPTI quarterly total operating expenses is $63.77 million, with the most recent change of -$5.67 million (-8.17%) on September 30, 2024.
- Over the past year, KPTI quarterly operating expenses has dropped by -$5.67 million (-8.17%).
- KPTI quarterly operating expenses is now -21.90% below its all-time high of $81.65 million, reached on June 30, 2022.
Performance
KPTI Quarterly Operating Expenses Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Operating Expenses Formula
Operating Expenses = Selling, General & Administrative (SG&A) Expenses + Research & Development (R&D) Expenses + Depreciation & Amortization + Other Operating Expenses
KPTI Operating Expenses Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -8.0% | -8.2% |
| 3 y3 years | -2.4% | -21.2% |
| 5 y5 years | +28.7% | +23.7% |
KPTI Operating Expenses Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | -11.2% | at low | -21.9% | at low |
| 5 y | 5-year | -11.2% | +18.8% | -21.9% | +6.3% |
| alltime | all time | -11.2% | +2486.6% | -21.9% | +1638.0% |
Karyopharm Therapeutics Operating Expenses History
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2024 | - | $63.77 M(-8.2%) |
| Jun 2024 | - | $69.44 M(+6.9%) |
| Mar 2024 | - | $64.97 M(-7.3%) |
| Dec 2023 | $270.63 M(-8.0%) | $70.07 M(+5.6%) |
| Sep 2023 | - | $66.36 M(+0.6%) |
| Jun 2023 | - | $65.96 M(-3.4%) |
| Mar 2023 | - | $68.25 M(+4.1%) |
| Dec 2022 | $294.06 M(-3.5%) | $65.58 M(-0.6%) |
| Sep 2022 | - | $66.00 M(-19.2%) |
| Jun 2022 | - | $81.65 M(+1.0%) |
| Mar 2022 | - | $80.83 M(+2.9%) |
| Dec 2021 | $304.69 M(+9.9%) | $78.56 M(-2.9%) |
| Sep 2021 | - | $80.91 M(+14.8%) |
| Jun 2021 | - | $70.51 M(-5.6%) |
| Mar 2021 | - | $74.70 M(+5.0%) |
| Dec 2020 | $277.23 M(+21.7%) | $71.11 M(+4.6%) |
| Sep 2020 | - | $68.00 M(-7.4%) |
| Jun 2020 | - | $73.44 M(+13.5%) |
| Mar 2020 | - | $64.67 M(+7.8%) |
| Dec 2019 | $227.76 M(+8.3%) | $59.97 M(+16.4%) |
| Sep 2019 | - | $51.54 M(+0.7%) |
| Jun 2019 | - | $51.18 M(-21.4%) |
| Mar 2019 | - | $65.08 M(+12.9%) |
| Dec 2018 | $210.22 M | $57.66 M(+16.7%) |
| Sep 2018 | - | $49.39 M(-8.9%) |
| Date | Annual | Quarterly |
|---|---|---|
| Jun 2018 | - | $54.22 M(+10.8%) |
| Mar 2018 | - | $48.94 M(+19.4%) |
| Dec 2017 | $132.14 M(+19.2%) | $40.99 M(+32.0%) |
| Sep 2017 | - | $31.05 M(+4.4%) |
| Jun 2017 | - | $29.75 M(-2.0%) |
| Mar 2017 | - | $30.35 M(+11.5%) |
| Dec 2016 | $110.89 M(-7.1%) | $27.21 M(+5.5%) |
| Sep 2016 | - | $25.79 M(-15.5%) |
| Jun 2016 | - | $30.54 M(+11.6%) |
| Mar 2016 | - | $27.35 M(-6.7%) |
| Dec 2015 | $119.33 M(+56.9%) | $29.33 M(-4.4%) |
| Sep 2015 | - | $30.68 M(-7.5%) |
| Jun 2015 | - | $33.16 M(+26.8%) |
| Mar 2015 | - | $26.15 M(+0.7%) |
| Dec 2014 | $76.08 M(+121.6%) | $25.96 M(+31.3%) |
| Sep 2014 | - | $19.77 M(+20.0%) |
| Jun 2014 | - | $16.47 M(+18.6%) |
| Mar 2014 | - | $13.88 M(+14.1%) |
| Dec 2013 | $34.34 M(+107.8%) | $12.17 M(+30.6%) |
| Sep 2013 | - | $9.32 M(+33.1%) |
| Jun 2013 | - | $7.00 M(+19.8%) |
| Mar 2013 | - | $5.84 M(+36.8%) |
| Dec 2012 | $16.52 M(+57.9%) | $4.27 M(+16.4%) |
| Sep 2012 | - | $3.67 M |
| Dec 2011 | $10.46 M | - |
FAQ
- What is Karyopharm Therapeutics annual total operating expenses?
- What is the all time high annual operating expenses for Karyopharm Therapeutics?
- What is Karyopharm Therapeutics annual operating expenses year-on-year change?
- What is Karyopharm Therapeutics quarterly total operating expenses?
- What is the all time high quarterly operating expenses for Karyopharm Therapeutics?
- What is Karyopharm Therapeutics quarterly operating expenses year-on-year change?
What is Karyopharm Therapeutics annual total operating expenses?
The current annual operating expenses of KPTI is $270.63 M
What is the all time high annual operating expenses for Karyopharm Therapeutics?
Karyopharm Therapeutics all-time high annual total operating expenses is $304.69 M
What is Karyopharm Therapeutics annual operating expenses year-on-year change?
Over the past year, KPTI annual total operating expenses has changed by -$23.43 M (-7.97%)
What is Karyopharm Therapeutics quarterly total operating expenses?
The current quarterly operating expenses of KPTI is $63.77 M
What is the all time high quarterly operating expenses for Karyopharm Therapeutics?
Karyopharm Therapeutics all-time high quarterly total operating expenses is $81.65 M
What is Karyopharm Therapeutics quarterly operating expenses year-on-year change?
Over the past year, KPTI quarterly total operating expenses has changed by -$5.67 M (-8.17%)